Anatara Lifesciences Ltd (ANR) AI Stock Analysis

• Market Cap: AU$1.28M
• Dividend Yield: N/A
• Average Volume (3M): 1.06M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.35
• Revenue Growth: N/A
• EPS Growth: 26.09%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 213,383,730
• 10 Day Avg. Volume: 3,048,202
• 30 Day Avg. Volume: 1,062,709
• PEG Ratio: 0.12
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Anatara Lifesciences Ltd is facing substantial financial challenges due to lack of revenue and ongoing losses, which significantly affect its overall stock score. The absence of technical analysis indicators and a concerning valuation further compound the risks. The company's debt-free status is a positive aspect but is outweighed by its financial instability.

Anatara Lifesciences Ltd Business Overview & Revenue Model

Company Description

Anatara Lifesciences Ltd (ANR) is an Australian biotechnology company that operates in the life sciences sector. The company is focused on developing products for human and animal health, particularly in the areas of gastrointestinal health. Anatara's core products include therapeutic and preventative solutions for conditions such as irritable bowel syndrome (IBS) in humans and gastrointestinal diseases in animals.

How the Company Makes Money

Anatara Lifesciences Ltd generates revenue through the development and commercialization of its proprietary health solutions. The company earns money by licensing its technologies and products to pharmaceutical and biotech companies, which in turn manufacture and distribute these solutions to the market. Anatara may also engage in strategic partnerships and collaborations to enhance its product development and market reach. Additionally, the company could receive milestone and royalty payments based on the success and sales of its licensed products.

Anatara Lifesciences Ltd Financial Statement Overview

Summary

Anatara Lifesciences Ltd faces significant financial challenges with no recent revenue generation and ongoing operational losses. While the company maintains a debt-free balance sheet, its negative cash flows and declining equity present risks to its financial health. Sustained efforts to generate revenue and improve operational efficiency are critical for future stability.

Income Statement

Anatara Lifesciences Ltd has had no revenue over the past few years, indicating a lack of sales or successful product commercialization. The company has consistently reported negative EBIT and net income, reflecting ongoing operational losses. The absence of revenue growth further highlights the financial challenges in generating income from its operations.

Balance Sheet

The balance sheet shows a relatively strong equity position with no debt, which suggests financial stability in terms of leverage. However, continuous losses have led to a decline in equity over time, which could limit future financing opportunities and investment in growth. The equity ratio remains healthy, indicating a strong asset base relative to liabilities.

Cash Flow

The company has experienced negative operating cash flows, indicating difficulties in generating cash from core operations. Free cash flow is also negative, reflecting the strain on financial resources. Financing activities have provided some relief, but consistent reliance on external funding could be unsustainable in the long term.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
250.51K	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-1.07M	-748.91K	-24.76K	-24.68K	-6.26K	-16.10K
	EBIT
-1.94M	-1.46M	-3.28M	-3.02M	-3.11M	-4.21M
	EBITDA
-1.94M	-1.46M	-3.21M	-2.97M	-3.01M	-4.01M
	Net Income Common Stockholders
-1.93M	-1.45M	-2.02M	-2.53M	-2.00M	-3.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.10M	982.11K	401.18K	1.17M	3.43M	2.68M
	Total Assets
1.76M	1.67M	1.42M	1.77M	4.33M	3.34M
	Total Debt
0.00	0.00	0.00	65.80K	79.92K	0.00
	Net Debt
-1.05M	-982.11K	-351.18K	-1.05M	-3.35M	-2.68M
	Total Liabilities
403.91K	306.85K	494.83K	403.35K	496.67K	486.96K
	Stockholders Equity
1.36M	1.36M	924.54K	1.36M	3.83M	2.86M
Cash Flow		Free Cash Flow
-1.86M	-1.25M	-2.26M	-2.24M	-2.10M	-2.73M
	Operating Cash Flow
-1.86M	-1.25M	-2.26M	-2.23M	-2.10M	-2.72M
	Investing Cash Flow
0.00	50.00K	-1.73K	-56.56K	-3.98K	4.05M
	Financing Cash Flow
1.88M	1.83M	1.49M	-22.44K	2.85M	0.00

Anatara Lifesciences Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%
CYP	43 Neutral	$45.19M	―	-75.39%	―	―	44.29%
IMU	37 Underperform	AU$164.27M	―	-99.05%	―	―	-34.09%
RCE	37 Underperform	AU$78.45M	―		―	―	-33.01%
ANR	27 Underperform	AU$1.28M	―	-147.32%	―	―	26.09%

Anatara Lifesciences Ltd Corporate Events

Anatara Lifesciences Secures R&D Funding to Propel Key Projects

Anatara Lifesciences has secured a $400,000 advance on its R&D Tax Incentive refund for FY2025 from a major shareholder group. This funding will support ongoing activities, including the GaRP-IBS trial and the Anti-Obesity Project, without the need for additional capital raising, thus helping the company progress its projects and restore shareholder value after recent mixed trial results.

Anatara Lifesciences Reports Mixed Results in GaRP-IBS Trial

Anatara Lifesciences Ltd announced mixed results for its GaRP-IBS Phase II trial, with the primary efficacy endpoint not being met, though secondary endpoints showed promising results in anxiety improvement and IBS-adequate relief. The company is reviewing its direction following these results and continues to explore commercial possibilities for its GaRP product in gastrointestinal health.

Anatara Lifesciences Reports GaRP-IBS Trial Results and Future Directions

Anatara Lifesciences Ltd has announced the completion of Stage 2 of its Phase II GaRP-IBS trial, revealing that while the primary efficacy endpoint was not met, significant findings were observed. The trial showed no safety concerns, and secondary endpoints indicated improvements in anxiety scores and IBS-Adequate Relief, suggesting potential benefits to the gut-brain axis. The company plans to leverage these findings for commercial opportunities and is also progressing with its anti-obesity project.

Anatara Lifesciences Advances GaRP-IBS Trial and Anti-Obesity Project

Anatara Lifesciences has announced that Stage 2 of its GaRP-IBS Phase II trial has entered the database lock process, with headline results expected soon. Despite the trial’s primary efficacy endpoint for IBS-SSS reduction versus placebo likely not being met, secondary endpoints show promise. The company is also progressing its Anti-Obesity Project, with pre-clinical mice studies underway, aiming to develop an oral medication to assist with weight reduction and maintenance.

Anatara Lifesciences Initiates Trading Halt Ahead of Key IBS Trial Update

Anatara Lifesciences Ltd has requested a trading halt on its securities pending an announcement concerning the Phase II GaRP-IBS Trial Stage 2. This move indicates a significant development in their research efforts, potentially impacting their market position and stakeholders’ interests as they await further details on the trial’s progress.

Anatara Lifesciences Announces Board Changes Amid Strategic Renewal

Anatara Lifesciences Ltd announced a change in its board, with the resignation of non-executive director Mr. Nicholas Haslam and the appointment of Mr. Jonathan Lindh as a non-executive director. This move aligns with Anatara’s ongoing board renewal process following the GaRP-IBS trial Stage 2 analysis. Mr. Lindh, who also serves as the Company Secretary, brings extensive legal and corporate governance experience, which is expected to support the company’s strategic objectives and enhance its industry positioning.

Anatara Lifesciences Reports Revenue Surge Amid Rising Losses

Anatara Lifesciences Ltd reported a significant increase in revenue by 92% to $523,261 for the half-year ending December 31, 2024, despite a 71% rise in net loss after tax to $1,161,074. The company did not declare any dividends, maintaining its focus on reinvesting in operations to strengthen its market position and address key financial elements impacting its performance.

Anatara Lifesciences Advances IBS Trial and Anti-Obesity Project

Anatara Lifesciences announced progress in their GaRP-IBS clinical trial and anti-obesity project. The GaRP-IBS trial is nearing completion of its second stage, with headline analysis expected in March 2025. The trial, which targets IBS symptoms, has paused recruitment to assess initial results. Meanwhile, ethics approval has been granted for pre-clinical studies in the anti-obesity project, aimed at developing an oral medication for weight control, indicating the company’s strategic focus on expanding its product pipeline.